To investigate CD13 expression flow cytometry was performed with a monoclonal PE-labeled anti-CD13 antibody. CD13 expression was found in 47% of the A549 lung cancer cells (green, control; purple, CD13) (Fig 3A). Following treatment with tTF-NGR (1 mg tTF-NGR/kg x5 (arrows); i.v.; n = 4 CD-1 nude mice) tumor growth of subcutaneous A549 xenotransplants was reduced as compared to the saline control group (n = 6) CD-1 nude mice (Fig 3B). The CD13 expression in subcutaneous A549 xenotransplant is demonstrated by immunofluorescence; since the antibodies used for CD13 and CD31 staining are speciesspecific for human CD13 and CD31, vascular and perivascular staining were not assayed in the xenografts (Fig 3C).
Citation: Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, et al. (2017) Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer. PLoS ONE 12(8): e0183201. https://doi.org/10.1371/journal.pone.0183201
Published: August 9, 2017
Copyright: © 2017 Schmidt et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.